Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Single-Arm Rollover Study to Evaluate Long-Term Safety in Subjects Who Participated in Other Celgene Sponsored CC-486 (Oral Azacitidine) Clinical Trials in Hematological Disorders

NCT02494258 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02494258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02494258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Single-Arm Rollover Study to Evaluate Long-Term Safety in Subjects Who Participated in Other Celgene Sponsored CC-486 (Oral Azacitidine) Clinical Trials in Hematological Disorders
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Completed
Start date
October 22, 2015
Completion date
April 14, 2025
Enrollment
5 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancies, hematologic neoplasm, neoplasms